News | July 26, 2024
Piramal Pharma Q1 FY25 net loss narrows
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
The inspections concluded with no Form 483 observations or significant critical findings
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
